Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- befree-2016 importedOn "2016-02-19" NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion wasGeneratedBy ECO_0000203 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion wasDerivedFrom befree-2016 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion SIO_000772 12615701 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion evidence source_evidence_literature NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion description "[Clinical studies testing the efficacy of COX inhibition as adjuvant therapy for ovarian cancer may see more beneficial effects with adjuvant therapy with either a COX-1 selective or nonselective cyclooxygenase inhibitor as compared with a COX-2 selective drug.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.